Company Overview and News

 
Tesla May Hit The Wall On Battery Capacity By 2022

2018-04-19 seekingalpha
Projected production rates for the Model 3, Tesla Semi, and Model Y would fully utilize that capacity.
Upvote Downvote

 
Nikkei gains to 7-week high helped by strong Wall Street, weak yen

2018-04-18 reuters
TOKYO, April 18 (Reuters) - Japan’s Nikkei share average raced to a seven-week high on Wednesday as risk sentiment recovered after Wall Street rose overnight on earnings hopes, while a weaker yen lifted shares across the board.
Upvote Downvote

 
Nikkei hits 7-week high as earnings hopes buoy Wall Street

2018-04-18 thehindubusinessline
The Nikkei rose 1.2 per cent to 22,109.48 in midmorning trade, after hitting a high of 22,136.21, its strongest level since February 28. - Reuters
Upvote Downvote

 
Nikkei gains to 7-week high as earnings hopes buoy Wall Street

2018-04-18 reuters
TOKYO, April 18 (Reuters) - Japan’s Nikkei share average raced to a seven-week high on Wednesday morning as risk sentiment recovered after Wall Street rose overnight on earnings hopes, lifting shares across the board.
Upvote Downvote

2
Lithium Investing: Capital Continues To Flow Into Lithium Assets As Demand Rises

2018-04-16 seekingalpha
Battery production continues to climb as automakers bring new options to market; new energy vehicle sales figures continue to rise.
Upvote Downvote

 
Tesla May Be the Most Hated (and Loved) Stock in America - Bloomberg

2018-04-13 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Nintendo teams up with venture fund to find new tech for Switch

2018-04-13 japantimes.co.jp
Nintendo Co. is teaming up with San Francisco-based Scrum Ventures to scout startups working on new ways to play or use the company’s hit gaming console, the Switch.
Upvote Downvote

 
Enphase Energy - A Diamond In The Rough

2018-04-10 seekingalpha
Enphase Energy's (ENPH) latest 10K puts the bankruptcy albatross to rest - "in connection with the issuance of our consolidated financial statements for the year ended 12/31/2016, we concluded that there was substantial doubt regarding our ability to continue as a going concern. We have taken and continue to take steps to improve our financial position, including raising additional capital, and we have concluded as of 12/31/2017, that substantial doubt in our ability to continue as a going concern, no longer exists".
Upvote Downvote

 
Vanadium Batteries Need Elon Musk Moment to Kick-Start Market - Bloomberg

2018-04-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
China Has the Cards to Call Trump's High-Stakes Trade Bet - Bloomberg

2018-04-06 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Japan faces losses on grain, production fronts if U.S.-China trade war erupts

2018-04-05 japantimes.co.jp
The escalating trade row between Washington and Beijing could impact Japanese companies that source production in China and export grain from U.S. subsidiaries. But many so far appear to be taking a wait-and-see approach on whether the world’s two largest economies will follow through on their proposed tariffs or find a solution that allows both to save face.
Upvote Downvote

 
No, Tesla Can't Borrow Much Against The Gigafactory

2018-03-29 seekingalpha
Well, Tesla does own the joint. It’s quite a big spread. And no one has a mortgage.
Upvote Downvote

 
Nikkei tumbles on ex-dividend adjustments, tech sell-off

2018-03-28 reuters
TOKYO, March 28 (Reuters) - Japanese stocks fell on Wednesday, led by a sell-off in tech firms after their U.S. counterparts skidded on concerns about government regulation, while ex-dividend trades added to the broader losses.
Upvote Downvote

 
Nikkei tumbles as tech shares hit by regulatory scare

2018-03-28 reuters
TOKYO, March 28 (Reuters) - Japanese stocks tumbled on Wednesday morning, led by a sell-off in tech firms after their U.S. counterparts skidded on concerns over government regulation, while shares going ex-dividend added to the broader losses in Tokyo.
Upvote Downvote

 
Ageing Japan: Robots may have role in future of elder care

2018-03-28 channelnewsasia
TOKYO: Paro the furry seal cries softly while an elderly woman pets it. Pepper, a humanoid, waves while leading a group of senior citizens in exercises. The upright Tree guides a disabled man taking shaky steps, saying in a gentle feminine voice, “right, left, well done!”
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 69832A205